Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475696 · ClinicalTrials.gov registry record · Phase 2
Urge Incontinence Bladder Overactivity Study
A Phase 2 study of Urinary Incontinence, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT00475696 is a Phase 2 study of Urinary Incontinence that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants, above the 256-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (17% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00475696, a Phase 2 study of Urinary Incontinence, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
Examine the efficacy and safety of duloxetine in subjects with symptoms of bladder overactivity due to pure detrusor instability or sensory urgency. Subjects in study will be permitted to escalate or de-escalate between 80 mg/day and 120 mg/day in consultation with the investigator and based on their adverse events.
Conditions Studied
Interventions
- DRUG Duloxetine
Study Locations (3)
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Indianapolis
Queensland
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Townsville
Ontario
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - North York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475696
The ClinicalTrials.gov registry entry for NCT00475696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 256-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (17% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Duloxetine is the first listed.
NCT00475696 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Queensland, Ontario.
Frequently Asked Questions
What is clinical trial NCT00475696 about?
NCT00475696 is a clinical study titled "Urge Incontinence Bladder Overactivity Study". Examine the efficacy and safety of duloxetine in subjects with symptoms of bladder overactivity due to pure detrusor instability or sensory urgency. Subjects in study will be permitted to escalate or de-escalate between 80 mg/day and 120 mg/day in consultation with the investigator and based on thei...
What is the current status of trial NCT00475696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2002-11. Estimated completion is 2005-03.
What conditions does trial NCT00475696 study?
This clinical trial studies the following conditions: Urinary Incontinence.
What interventions are being tested in trial NCT00475696?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00475696?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00475696 being conducted?
This trial has 3 study locations across Indiana, Queensland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
RECRUITING · Phase 2
-
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
RECRUITING · Phase 2
-
Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
COMPLETED · Phase 2
-
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
COMPLETED · Phase 2
-
Translating Unique Learning for Incontinence Prevention
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.